Analystreport

Regeneron (NASDAQ: REGN) had its price target lowered by analysts at Canaccord Genuity from $356.00 to $304.00. They now have a "hold" rating on the stock.

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com